Abstract: Objective: To assess 6 enzyme -linked immunosorbent assays (ELISA), namely, EBNA1-IgA, EBNA1-IgG, Zta-IgA, Zta-IgG, VCA-p18-IgA and VCA-p18-IgG, for their application in serodiagnosis of nasopharyngeal carcinoma (NPC), and to investigate what combinations of ELISAs were more efficient. Methods: The sera of 85 pretreated NPC patients and 132 healthy adults were collected. Six ELISAs using Epstein-Barr virus (EBV) -specific recombinant fusion proteins were applied to test the serum antibody level against EBV. Sensitivity, specificity, odds ratio and other parameters were evaluated to determine the efficiency of diagnosing NPC. Results: When evaluated individually, the sensitivity and specificity of Zta-IgG and EBNA1-IgA could both reach more than 0.8106. The specificity of dual positives for Zta-IgG/EBNA1-IgG and Zta-IgG/EBNA1-IgA increased to more than 0.9621. The triple positivity for Zta-IgG/EBNA1-IgA/EBNA1-IgG and Zta-IgG/EBNA1-IgG/ZtaIgA could not only enhance the specificity toward 0.9824 but also significantly elevate the odds ratio (206.4242 and 196.5000 respectively). None of the 85 NPC patients' sera were negative when the ZtaIgG/EBNA1-IgA/EBNA1-IgG tests were conducted concurrently. Conclusions: When using a single ELISA merely for serodiagnosis of NPC, the best choice is either the Zta-IgG or EBNA1-IgA. In order to enhance the specificity, the combined usage of 2 ELISAs, namely, Zta-IgG/EBNA1-IgA or Zta-IgG/ EBNA1-IgG, was appropriate. Three ELISAs used concurrently could not only enhance the specificity, but also meet the requirement of excluding suspicious NPC patients serologically. Two combinations of 3 ELISAs, namely, Zta-IgG/EBNA1-IgA/EBNA1-IgG and Zta-IgG/ EBNA1-IgG/Zta-IgA were recommended.